E-Folder - Business

If you have a public company, or are anticipating taking your company public, the subject of stock support, often ignored, should be a critical part of your corporate planning.

It is the foundation for the success of yo

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ur stock values. This is how you will ensure that your share price is at its highest possible level at the time a buyout or merger offer is made for your company.

Growing Your Business

Private companies go pub

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

ic to grow their business. Being a public company makes it easier to access money, the lifeblood of business. You convert your equity to cash. It's easier for a public company to borrow money. You can buy corporate a

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

sets with stock. Eventually, you will sell your public company based upon its share price and not its balance sheet. These benefits depend upon your ability to maintain a strong share price.

Better Marketing

B

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

tter marketing, not better mousetraps, creates strong share prices. To ensure that the stock is both strong and stable, your corporate vision must become the vision of your shareholders. You must effectively tell your

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

tory to the financial community.

Better marketing means educating the investment community about your company and your industry. It means developing personal relationships with your shareholders and market makers. I

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

means being honest about your company and leveling with your supporters. It means expanding the demand for your stock beyond the limits of North America.

Corporate Behavious

There are several ethical rules of

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

corporate behaviour you must follow:

* Understate, never overstate your positives. (Enron?)

* Communicate in good times and bad. (It's vital to have a vice president of investor relations, whose sole job is to co

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

municate with your shareholders and the financial community.)

* Investor relations programs should rely on filings over news releases.

* Investor relations programs should aim to diversify the shareholder bas

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

.

Business Strategy

You must develop a coherent business strategy stating clear performance, profitability, and expansion goals. The strategy must then be translated into an appropriate investment message. It m

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

st target investors with similar goals and economic objectives.

* A company that doesn't communicate effectively will fail.

* A company should list its investor relations goals.

* A company should target its i

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

nvestor audience.

* An outside investor relations program should list strategies and expected results.

* You need a story to tell.

* People do business with companies they trust. If you want the financial

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

community to believe you, level with them.

* Know your message.

* Doing what's right is good business.

Maintaining A Strong Share Price

You need a strong share price to buy assets without diluting your

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

issued stock to the point where it makes it impossible to keep a strong share price.

If your share price bounces down, you create selling barriers which, when you attempt to move it back up, motivate present sharehold

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

rs to dump their stock into your efforts.

Unstable share prices attract short sellers. Unstable share prices attract regulators.

Strong share prices are essential to get your company listed on stock exchanges in this

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

country and elsewhere. Strong share prices make bankers happy when they consider lending your company money.

The list is endless. There is no advantage to having a penny stock. There are loads of disadvantages.

S

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

pporting Your Share Price

You must support your stock price whether you use our private placement program, do an initial public offering or any other public offering. My associate’s company considers this concept

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

o critical, for instance, that his investors provide and fund a powerful five-year external stock support program to bolster and extend the value of clients' insider programs. Combined, the two programs can create a st

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ong marketing effort for a stock in the United States, the United Kingdom and Europe. They will also ensure a high value at merger/acquisition time.

Remember that selling the concept of owning your stock is just as

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ritical as selling the concept of using your product or service. The customer list may be different, but both represent profit potential for you and your company and a Golden Parachute four or five years in your future

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

Tags

Links

E-Folder - Treat Your Company's Stock Like Any Other Product Or Service

Related Articles: